Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14251172 | 0.91 | — | — | |
| SCHEMBL15074245 | 0.91 | — | — | |
| SCHEMBL313343 | 0.91 | — | — | |
| Methylene Chloride SCHEMBL10495455 | 0.89 | POLB (0.38) | POLBLMNAUSP2SMN1; SMN2HPGD | |
| Water SCHEMBL1315360 | 0.89 | — | — | |
| Ammonia Solution, Strong SCHEMBL11240480 | 0.89 | — | — | |
| Hydrochloric Acid SCHEMBL27837501 | 0.89 | — | — | |
| Methyl Alcohol SCHEMBL2743758 | 0.87 | KMT2A (0.40) | POLBLMNAUSP2SMN1; SMN2HPGD | |
| Hydrogen Sulfide SCHEMBL28792291 | 0.86 | POLB (0.40) | POLBLMNAUSP2SMN1; SMN2HPGD | |
| SCHEMBL1961398 | 0.85 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2272854-B1 | NOVEL GLYCOLIPID AND USE THEREOF | RIKEN (JP) | 2015-08-05 | — | — | EP | disclosed |
| US-8551959-B2 | Glycolipid and use thereof | RIKEN (JP) | 2013-10-08 | — | — | US | disclosed |
| US-20110104188-A1 | NOVEL GLYCOLIPID AND USE THEREOF | RIKEN (JP) | 2011-05-05 | — | — | US | disclosed |
| EP-2272854-A1 | NOVEL GLYCOLIPID AND USE THEREOF | Riken (JP) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104188-A1 | NOVEL GLYCOLIPID AND USE THEREOF | SGMS1, UGCG, SGPL1 | POLB 4117/4885LMNA 4120/4885USP2 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.